Affilogic
Biotechnology company developing and applying a small, hyperstable protein scaffold platform (Nanofitins) for discovery, engineering and combination of affinity binders. Activities include in‑vitro library discovery, computational design, conjugation to payloads or materials, delivery-focused programs (brain, pulmonary, oral, tumor targeting), and collaborative early‑stage R&D and licensing with pharmaceutical partners.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Nanofitins
A novel alternative scaffold deriving from the bacterial protein Sac7d, engineered to provide specific, high-affinity binding to any target while maintaining high thermal and acid stability.
Nanofitins Combination
Nanofitins can be assembled in multimers for enhanced avidity or for multi-specificity, combining up to five Nanofitins as one multivalent compound with retained individual affinity.
Respitude
Inhaled antiviral therapeutics against respiratory infections utilizing pulmonary delivered Nanofitins® for influenza and SARS-CoV-2.
NanoVector
A proprietary delivery system utilizing Nanofitins to deliver therapeutic compounds to specific cells and organs via receptor-mediated cell uptake.
Bus2Brain
A Nanofitin-based shuttle developed by Affilogic for enhanced brain delivery of nucleic acid therapies and biologics utilizing receptor-mediated transcytosis via the transferrin receptor.
OncoFitin-Drug-Conjugate: anti-Mesothelin Nanofitin-MMAE conjugate
An OncoFitin-Drug-Conjugate utilizing anti-Mesothelin Nanofitin conjugated with MMAE for targeted drug delivery against solid tumors.
Nanofitins
A novel alternative scaffold deriving from the bacterial protein Sac7d, engineered to provide specific, high-affinity binding to any target while maintaining high thermal and acid stability.
Nanofitins Combination
Nanofitins can be assembled in multimers for enhanced avidity or for multi-specificity, combining up to five Nanofitins as one multivalent compound with retained individual affinity.
Respitude
Inhaled antiviral therapeutics against respiratory infections utilizing pulmonary delivered Nanofitins® for influenza and SARS-CoV-2.
NanoVector
A proprietary delivery system utilizing Nanofitins to deliver therapeutic compounds to specific cells and organs via receptor-mediated cell uptake.
Bus2Brain
A Nanofitin-based shuttle developed by Affilogic for enhanced brain delivery of nucleic acid therapies and biologics utilizing receptor-mediated transcytosis via the transferrin receptor.
OncoFitin-Drug-Conjugate: anti-Mesothelin Nanofitin-MMAE conjugate
An OncoFitin-Drug-Conjugate utilizing anti-Mesothelin Nanofitin conjugated with MMAE for targeted drug delivery against solid tumors.
Services
In vitro generation and screening of scaffold libraries to identify high‑affinity, target‑specific binders for research and early‑stage therapeutic programs.
Design and production of scaffold‑based vectors for targeted delivery of payloads (small molecules, biologics, nanoparticles, radionuclides, oligonucleotides, CAR‑T).
Development and testing of orally deliverable scaffold therapeutics and spray‑dried pulmonary formulations compatible with single‑dose inhalers.
Design and implementation of affinity binders conjugated to chromatographic supports to simplify and improve purification of vaccines and other biologics.
Research collaborations, option/license agreements and sponsored programs to co‑develop scaffold‑based therapeutics and delivery solutions.
In vitro generation and screening of scaffold libraries to identify high‑affinity, target‑specific binders for research and early‑stage therapeutic programs.
Design and production of scaffold‑based vectors for targeted delivery of payloads (small molecules, biologics, nanoparticles, radionuclides, oligonucleotides, CAR‑T).
Development and testing of orally deliverable scaffold therapeutics and spray‑dried pulmonary formulations compatible with single‑dose inhalers.
Design and implementation of affinity binders conjugated to chromatographic supports to simplify and improve purification of vaccines and other biologics.
Research collaborations, option/license agreements and sponsored programs to co‑develop scaffold‑based therapeutics and delivery solutions.
Expertise Areas
- Protein engineering and scaffold design
- In vitro binder discovery and library screening
- Computational protein design and immunogenicity assessment
- Targeted drug delivery (brain shuttle, pulmonary, oral, tumor targeting)
Key Technologies
- In vitro library screening
- Computational protein design
- Genetic fusion and click chemistry conjugation
- GMP bacterial fermentation
News & Updates
Regular scientific presentations and posters at conferences covering nasal/pulmonary delivery, PEGS, PEGS Europe, World Vaccine Congress, BIO and other partnering events.
Awarded UBISTART Prize for a project on discovery and development of the scaffold class as GPCR modulators.
Won award for best pitch among selected startups at the Rencontres Internationales de Biotechnologie (theme: immuno‑oncology).
Regular scientific presentations and posters at conferences covering nasal/pulmonary delivery, PEGS, PEGS Europe, World Vaccine Congress, BIO and other partnering events.
Awarded UBISTART Prize for a project on discovery and development of the scaffold class as GPCR modulators.
Won award for best pitch among selected startups at the Rencontres Internationales de Biotechnologie (theme: immuno‑oncology).